TCOV
ALDR

Trust Company of Vermont’s Alder Biopharmaceuticals ALDR Stock Holding History

Trust Company of Vermont’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2
Closed – – 1011
2017
Q2 		$0 Buy
+2
New +$37 ﹤0.01% 1016

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Trust Company of Vermont's ALDR Position: Q3 2017 in Review

Trust Company of Vermont sold out of Alder Biopharmaceuticals (ALDR) in Q3 2017, closing a stake of 2 shares.

Trust Company of Vermont first reported a position in ALDR in Q2 2017 and held it in 1 quarter. The position peaked at $0 in Q2 2017. 132 funds tracked by Wall St. Rank hold ALDR as of Q3 2017.

  • Trust Company of Vermont reported no remaining Alder Biopharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Trust Company of Vermont sold 2 Alder Biopharmaceuticals shares in Q3 2017.
  • Trust Company of Vermont first reported a position in Alder Biopharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Trust Company of Vermont's Alder Biopharmaceuticals position peaked at $0 in Q2 2017.
  • 132 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2017.

Based on Trust Company of Vermont's 13F filing for Q3 2017, filed 24 Oct 2017.